Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.85 |
| ▸ | PRKACA | P17612 | 4/20 | 0.79 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.79 |
| ▸ | AKT2 | P31751 | 2/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.79 |
| ▸ | PIM1 | P11309 | 2/20 | 0.79 |
| ▸ | GSK3A | P49840 | 2/20 | 0.79 |
| ▸ | GSK3B | P49841 | 2/20 | 0.79 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.79 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.79 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.79 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.79 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.79 |
| ▸ | CDC7 | O00311 | 1/20 | 0.79 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.79 |
| ▸ | CHUK | O15111 | 1/20 | 0.79 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.79 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.79 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| A-443654 SCHEMBL29644958 | 1.00 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2ROCK2 | |
| A-443654 SCHEMBL6855479 | 1.00 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2ROCK2 | |
| A-443654 SCHEMBL29374078 | 1.00 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2ROCK2 | |
| A-443654 SCHEMBL19859268 | 1.00 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2ROCK2 | |
| SCHEMBL6854512 | 0.93 | AKT1 (0.73) | AKT1PRKACAAKT3AKT2ROCK2 | |
| SCHEMBL6855274 | 0.92 | AKT1 (1.00) | AKT1PRKACAAKT3AKT2ROCK2 | |
| SCHEMBL6854290 | 0.91 | AKT1 (0.81) | AKT1PRKACAAKT3AKT2ROCK2 | |
| SCHEMBL6854548 | 0.90 | AKT1 (1.00) | AKT1PRKACAAKT3AKT2ROCK2 | |
| SCHEMBL7161667 | 0.90 | AKT1 (1.00) | AKT1PRKACAAKT3AKT2ROCK2 | |
| SCHEMBL2738468 | 0.90 | AKT1 (0.78) | AKT1PRKACAAKT3AKT2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | claimed |
| EP-3733178-A1 | AGENTS AND METHODS FOR TREATING AND PREVENTING SEBORRHEIC KERATOSIS | The General Hospital Corporation (US) | 2020-11-04 | — | — | EP | claimed |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-06-13 | — | — | US | claimed |
| EP-3493818-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | The Wistar Institute Of Anatomy And Biology (US) | 2019-06-12 | — | — | EP | claimed |
| WO-2018031407-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-15 | — | — | WO | claimed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | claimed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | claimed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | claimed |
| US-12195804-B2 | Treatment of squamous cell carcinoma | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-04-14 | — | — | US | disclosed |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20070225315-A1 | Methods of Treating Muscular Wasting Diseases Using NF-kB Activation Inhibitors | THERALOGICS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225315-A1 | Methods of Treating Muscular Wasting Diseases Using NF-kB Activation Inhibitors | THERALOGICS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007106884-A2 | METHODS OF TREATING MUSCULAR WASTING DISEASES USING NF-KB ACTIVATION INHIBITORS | THERALOGICS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195804-B2 | Treatment of squamous cell carcinoma | MTOR, PIK3CA, RICTOR | AKT1 8/4885PRKACA 172/4885AKT3 5/4885 |
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885PRKACA 27/4885AKT3 156/4885 |
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885PRKACA 270/4885AKT3 257/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885PRKACA 27/4885AKT3 156/4885 |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885PRKACA 270/4885AKT3 257/4885 |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885PRKACA 270/4885AKT3 257/4885 |
| US-20070225315-A1 | Methods of Treating Muscular Wasting Diseases Using NF-kB Activation Inhibitors | NFKBIA, IKBKB, NFKB2 | AKT1 1034/4885PRKACA 1095/4885AKT3 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.